NexgenRx (TSXV:NXG) Loans Receivable: C$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NXG NexgenRx Inc TSXV:NXG
50 GF Score
Price C$0.61
GF Value C$0.33
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is NexgenRx Loans Receivable?

NexgenRx TSXV:NXG 50 Loans Receivable is C$0.00 Mil as of Jun. 2026. GuruFocus rates TSXV:NXG with a GF Score™ of 50/100 and a GF Value™ of C$0.33 (Significantly Overvalued). The stock has 3 warning signs investors should review.

NexgenRx's Loans Receivable for the quarter that ended in Jun. 2026 was C$0.00 Mil.

NexgenRx's annual Loans Receivable stayed the same from Dec. 2023 (C$0.05 Mil) to Dec. 2024 (C$0.05 Mil) but then declined from Dec. 2024 (C$0.05 Mil) to Dec. 2025 (C$0.00 Mil).

NexgenRx Loans Receivable Historical Data

* Premium members only.

The historical data trend for NexgenRx's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexgenRx Loans Receivable Chart

NexgenRx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.05 0.05 0.00

NexgenRx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.00 0.00 0.00 0.00
TSXV:NXG
50GF Score
NexgenRx Inc TSXV:NXG
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NexgenRx Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of C$0.00 Mil mean?
NexgenRx (TSXV:NXG) has a Loans Receivable of C$0.00 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on NexgenRx and its competitors.
Is NexgenRx's Loans Receivable too high?
NexgenRx's current Loans Receivable is C$0.00 Mil. Overall, NexgenRx has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's Loans Receivable compare to VEEV and BTSG?
NexgenRx's Loans Receivable of C$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Healthcare Providers & Services company?
A good Loans Receivable depends on the Healthcare Providers & Services industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on NexgenRx and its competitors. NexgenRx's current Loans Receivable is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (TSXV:NXG) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.33, compared to a current price of C$0.61 — trading 84.8% above its estimated fair value. The current Loans Receivable is C$0.00 Mil. NexgenRx's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For NexgenRx (TSXV:NXG), the current Loans Receivable is C$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NexgenRx (TSXV:NXG) Overvalued in 2026?

Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued. The current stock price of C$0.61 is trading 84.8% above its estimated GF Value™ of C$0.33. GuruFocus considers NexgenRx to be Significantly Overvalued.

Key valuation signals for TSXV:NXG:

  • Loans Receivable: C$0.00 Mil
  • GF Value™: C$0.33 vs. price of C$0.61 (84.8% above fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the TSXV:NXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NexgenRx Business Description

Other Exchanges NEGXF:USA
Address 191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
50GF Score

Get the complete analysis for TSXV:NXG

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.61
Price
C$0.33
GF Value